CMBA
TRDA icon

C.M. Bidwell & Associates’s Entrada Therapeutics TRDA Stock Holding History

C.M. Bidwell & Associates’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-29
Closed -$262 – 494
2025
Q1 		$262 Sell
29
-183
-86% -$2.28K ﹤0.01% 431
2024
Q4 		$3.67K Buy
212
+183
+631% +$3.32K ﹤0.01% 379
2024
Q3 		$463 Hold
29
– – ﹤0.01% 468
2024
Q2 		$413 Buy
+29
New +$412 ﹤0.01% 451

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

C.M. Bidwell & Associates's TRDA Position: Q2 2025 in Review

C.M. Bidwell & Associates sold out of Entrada Therapeutics (TRDA) in Q2 2025, closing a stake of 29 shares — an estimated $262 sold.

C.M. Bidwell & Associates first reported a position in TRDA in Q2 2024 and held it in 4 quarters. The position peaked at $3.67K in Q4 2024. 107 funds tracked by Wall St. Rank hold TRDA as of Q2 2025.

  • C.M. Bidwell & Associates reported no remaining Entrada Therapeutics position as of Q2 2025 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 29 Entrada Therapeutics shares in Q2 2025, an estimated $262.
  • C.M. Bidwell & Associates first reported a position in Entrada Therapeutics in Q2 2024 and held it in 4 quarters.
  • C.M. Bidwell & Associates's Entrada Therapeutics position peaked at $3.67K in Q4 2024.
  • 107 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2025.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2025, filed 14 Aug 2025.